239 related articles for article (PubMed ID: 28153606)
1. Herpesvirus DNA polymerases: Structures, functions and inhibitors.
Zarrouk K; Piret J; Boivin G
Virus Res; 2017 Apr; 234():177-192. PubMed ID: 28153606
[TBL] [Abstract][Full Text] [Related]
2. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
3. DNA polymerases of herpesviruses and their inhibitors.
Piret J; Boivin G
Enzymes; 2021; 50():79-132. PubMed ID: 34861944
[TBL] [Abstract][Full Text] [Related]
4. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents.
Thomsen DR; Oien NL; Hopkins TA; Knechtel ML; Brideau RJ; Wathen MW; Homa FL
J Virol; 2003 Feb; 77(3):1868-76. PubMed ID: 12525621
[TBL] [Abstract][Full Text] [Related]
5. Two-Metal Ion-Dependent Enzymes as Potential Antiviral Targets in Human Herpesviruses.
DiScipio KA; Weerasooriya S; Szczepaniak R; Hazeen A; Wright LR; Wright DL; Weller SK
mBio; 2022 Feb; 13(1):e0322621. PubMed ID: 35073739
[TBL] [Abstract][Full Text] [Related]
6. Genotypic characterization of herpes simplex virus DNA polymerase UL42 processivity factor.
Burrel S; Aït-Arkoub Z; Agut H; Boutolleau D
Antiviral Res; 2012 Jan; 93(1):199-203. PubMed ID: 22061617
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis and putative role in resistance to antivirals of the human cytomegalovirus DNA polymerase UL44 processivity factor.
Boutolleau D; Deback C; Bressollette-Bodin C; Conan F; Aït-Arkoub Z; Imbert-Marcille BM; Agut H
Antivir Ther; 2009; 14(6):847-52. PubMed ID: 19812447
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.
Loregian A; Rigatti R; Murphy M; Schievano E; Palu G; Marsden HS
J Virol; 2003 Aug; 77(15):8336-44. PubMed ID: 12857903
[TBL] [Abstract][Full Text] [Related]
9. Specific residues in the connector loop of the human cytomegalovirus DNA polymerase accessory protein UL44 are crucial for interaction with the UL54 catalytic subunit.
Loregian A; Appleton BA; Hogle JM; Coen DM
J Virol; 2004 Sep; 78(17):9084-92. PubMed ID: 15308704
[TBL] [Abstract][Full Text] [Related]
10. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
Schnute ME; Cudahy MM; Brideau RJ; Homa FL; Hopkins TA; Knechtel ML; Oien NL; Pitts TW; Poorman RA; Wathen MW; Wieber JL
J Med Chem; 2005 Sep; 48(18):5794-804. PubMed ID: 16134946
[TBL] [Abstract][Full Text] [Related]
11. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Tchesnokov EP; Gilbert C; Boivin G; Götte M
J Virol; 2006 Feb; 80(3):1440-50. PubMed ID: 16415021
[TBL] [Abstract][Full Text] [Related]
12. Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet.
Zarrouk K; Zhu X; Pham VD; Goyette N; Piret J; Shi R; Boivin G
Antimicrob Agents Chemother; 2021 Jun; 65(7):e0039021. PubMed ID: 33875432
[TBL] [Abstract][Full Text] [Related]
13. Distribution and effects of amino acid changes in drug-resistant α and β herpesviruses DNA polymerase.
Topalis D; Gillemot S; Snoeck R; Andrei G
Nucleic Acids Res; 2016 Nov; 44(20):9530-9554. PubMed ID: 27694307
[TBL] [Abstract][Full Text] [Related]
14. Herpes Simplex Virus 1 DNA Polymerase RNase H Activity Acts in a 3'-to-5' Direction and Is Dependent on the 3'-to-5' Exonuclease Active Site.
Lawler JL; Mukherjee P; Coen DM
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237844
[TBL] [Abstract][Full Text] [Related]
15. A mutation in the DNA polymerase accessory factor of herpes simplex virus 1 restores viral DNA replication in the presence of raltegravir.
Zhou B; Yang K; Wills E; Tang L; Baines JD
J Virol; 2014 Oct; 88(19):11121-9. PubMed ID: 25008933
[TBL] [Abstract][Full Text] [Related]
16. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
[TBL] [Abstract][Full Text] [Related]
17. Residues of human cytomegalovirus DNA polymerase catalytic subunit UL54 that are necessary and sufficient for interaction with the accessory protein UL44.
Loregian A; Appleton BA; Hogle JM; Coen DM
J Virol; 2004 Jan; 78(1):158-67. PubMed ID: 14671097
[TBL] [Abstract][Full Text] [Related]
18. Physical mapping of drug resistance mutations defines an active center of the herpes simplex virus DNA polymerase enzyme.
Knopf KW; Kaufman ER; Crumpacker C
J Virol; 1981 Sep; 39(3):746-57. PubMed ID: 6270349
[TBL] [Abstract][Full Text] [Related]
19. Herpesvirus DNA polymerase: Structures, functions, and mechanisms.
Coen DM; Lawler JL; Abraham J
Enzymes; 2021; 50():133-178. PubMed ID: 34861935
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of herpes group virus-induced DNA polymerases.
Mar EC; Huang ES
Intervirology; 1979; 12(2):73-83. PubMed ID: 231586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
